Apellis Pharmaceuticals (NASDAQ:APLS) reported its fourth-quarter 2024 earnings, revealing a significant revenue increase and a narrower-than-expected loss per share. The company posted an actual EPS ...

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.73 per share a year ago.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

STOCKHOLM, Feb. 27, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for ...

Apellis Pharmaceuticals Inc (NASDAQ:APLS) is set to release its Q4 2024 earnings on Feb 28, 2025. The consensus estimate for Q4 2024 revenue is $198.35 million, and the earnings are expected to ...

Boliden AB (publ) (OTCMKTS:BDNNY – Get Free Report) has earned an average recommendation of “Reduce” from the six analysts that are presently covering the firm, MarketBeat reports.

Highlights:,Upcoming quarterly earnings report scheduled for the end of February featuring a minor loss per share alongside substantial revenue.,Active engagement in the biopharmaceutical sector with ...

In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against the other oversold pharma stocks to buy according to analysts. On February 20 ...